Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
1.
Nutr Hosp ; 33(4): 404, 2016 Jul 19.
Article in Spanish | MEDLINE | ID: mdl-27571679

ABSTRACT

La deficiencia de vitamina A es infrecuente en los países desarrollados. La cirugía bariátrica constituye un factor de riesgo de deficiencia de esta vitamina. Se han descrito varios casos en pacientes sometidos a técnicas con un importante componente malabsortivo, como la derivación biliopancreática. En este artículo se describe un caso de deficiencia clínica de vitamina A con manifestaciones oculares y cutáneas tras bypass gástrico y se revisan las publicaciones sobre este tema y las recomendaciones para la prevención de esta importante complicación.


Subject(s)
Gastric Bypass/adverse effects , Postoperative Complications/therapy , Vitamin A Deficiency/etiology , Vitamin A Deficiency/therapy , Adult , Blindness/etiology , Blindness/therapy , Humans , Male , Skin Diseases/etiology , Skin Diseases/therapy
2.
Nutr. hosp ; 33(4): 1008-1011, jul.-ago. 2016. tab
Article in Spanish | IBECS | ID: ibc-154931

ABSTRACT

La deficiencia de vitamina A es infrecuente en los países desarrollados. La cirugía bariátrica constituye un factor de riesgo de deficiencia de esta vitamina. Se han descrito varios casos en pacientes sometidos a técnicas con un importante componente malabsortivo, como la derivación biliopancreática. En este artículo se describe un caso de deficiencia clínica de vitamina A con manifestaciones oculares y cutáneas tras bypass gástrico y se revisan las publicaciones sobre este tema y las recomendaciones para la prevención de esta importante complicación (AU)


Vitamin A deficiency is uncommon in developed countries. Bariatric surgery emerges a an important risk factor for vitamin A defi ciency and some clinical cases have been described, specially associated with malabsorptive surgical techniques, such as biliopancreatic diversion. In this paper we report a clinical case of a patient who developed blindness, ophthalmological disease and cutaneous alterations secondary to vitamin A deficiency after gastric bypass. A review of other publications and recommendations on this important subject is also included (AU)


Subject(s)
Humans , Male , Adult , Vitamin A/therapeutic use , Vitamin A Deficiency/complications , Vitamin A Deficiency/diet therapy , Bariatric Surgery/instrumentation , Bariatric Surgery/methods , Bariatric Surgery , Bariatric Medicine/methods , Gastric Bypass/methods , Blindness/complications , Blindness/diagnosis , Eye Diseases/complications , Eye Diseases/diagnosis , Obesity/complications , Obesity/diet therapy , Tomography, Emission-Computed/instrumentation , Tomography, Emission-Computed/methods , Micronutrients/therapeutic use , Blood Proteins/therapeutic use , Fat Soluble Vitamins/therapeutic use
3.
Mov Disord ; 23(8): 1130-6, 2008 Jun 15.
Article in English | MEDLINE | ID: mdl-18442107

ABSTRACT

Continuous subcutaneous apomorphine infusion (CSAI) is, at present, an alternative option for advanced Parkinson's disease (PD) with motor fluctuations. We studied the evolution of patients with PD and severe motor fluctuations long-term treated with CSAI. We reviewed data from 82 patients with PD (mean age, 67 +/- 11.07; disease duration, 14.39 +/- 5.7 years) and severe motor fluctuations referred to 35 tertiary hospitals in Spain. These patients were long-term treated (for at least 3 months) with CSAI and tolerated the procedure without serious side effects. We compared the baseline data of these 82 patients (before CSAI) with those obtained from the last follow-up visit of each patient. The mean follow-up of CSAI was 19.93 +/- 16.3 months. Mean daily dose of CSAI was 72.00 +/- 21.38 mg run over 14.05 +/- 1.81 hours. We found a statistically significant reduction in off-hours, according to self-scoring diaries (6.64 +/- 3.09 vs. 1.36 +/- 1.42 hours/day, P < 0.0001), total and motor UPDRS scores (P < 0.0001), dyskinesia severity (P < 0.0006), and equivalent dose of antiparkinsonian therapy (1,405 +/- 536.7 vs. 800.1 +/- 472.9 mg of levodopa equivalent units P < 0.0001). CSAI is an effective option for patients with PD and severe fluctuations, poorly controlled by conventional oral drug treatment.


Subject(s)
Antiparkinson Agents/administration & dosage , Apomorphine/administration & dosage , Parkinson Disease/drug therapy , Activities of Daily Living/classification , Adult , Aged , Aged, 80 and over , Female , Follow-Up Studies , Gait/drug effects , Humans , Infusion Pumps , Long-Term Care , Male , Middle Aged , Motor Activity/drug effects , Neurologic Examination/drug effects , Parkinson Disease/diagnosis , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...